ARTICLE

Synthesis and thermal denaturation studies of novel 2 -*O***,3 -***C***-linked bicyclic oligonucleotides with a methoxy or a piperazino group facing the major groove of nucleic acid duplexes†**

Michael Raunkjær,*^a* **Mads D. Sørensen***^b* **and Jesper Wengel****^a*

^a Nucleic Acid Center‡*, Department of Chemistry, University of Southern Denmark, DK-5230,*

Odense M, Denmark. E-mail: jwe@chem.sdu.dk; Fax: 45 6615 8780; Tel: 45 6550 2510

^b Department of Chemistry, University of Copenhagen, Universitetsparken 5, DK-2100, Copenhagen, Denmark

Received 20th September 2004, Accepted 26th October 2004 First published as an Advance Article on the web 18th November 2004

With the aim of evaluating duplex stabilities of oligonucleotides (ONs) with major groove facing functionalities, two novel 2 -*O*,3 -*C*-linked bicyclic nucleoside phosphoramidite building blocks were synthesized by routes involving regioselective O-methylation or piperazine attachment using carbonyldiimidazole coupling chemistry. The novel monomers were incorporated into 9-mer mixed base ONs and the thermal stability toward complementary single stranded DNA and RNA was evaluated by thermal denaturation experiments. O-methylated ONs confirmed the applicability of the functionalized bicylic sugar unit for attachment of groups facing the major groove and satisfactory binding properties towards the RNA complement were observed. For the piperazino modified ONs, experiments were performed in aqueous buffers with low (40 mM) and medium (110 mM) salt concentrations, at pH 5 and pH 7. A change from a medium to a low salt concentration induced a significant relative increase in the thermal stability of modified duplexes toward both DNA and RNA complements, which suggests protonation of the piperazino group under the experimental conditions applied. **Example of Contents for the Contents of Contents**

Introduction

Oligonucleotides (ONs) and analogues have found a widespread application in the fields of therapeutics, biotechnology and nanotechnology.**1,2** They form well defined and organized structures due to their unique hybridization properties. Chemical modifications or functionalization of ONs allow modulation of both chemical and physiological properties, which include altered affinity towards complementary strands, nuclease stability and RNase H activity. Successful attempts to modify ONs have been performed by introducing a cationic group linked to the base,**3–11** phosphate**12–17** or sugar**18–26** moieties, aimed at enhancing the affinity towards a complementary strand by net charge reduction of the duplex.

We have previously synthesized three 2 ,3 -BcNAs (**P**, **X** and **Y**; Fig. 1, $T =$ thymin-1-yl), with each showing interesting binding properties towards complementary RNA when incorporated into a modified ON.**27,28** Modification **P**, constituting a simple bicylic scaffold, showed an enhanced affinity towards complementary RNA when built into an almost fully modified 5 -**P**13T sequence.**²⁷** This result encouraged us to synthesize functionalized bicyclic structures, namely the diastereoisomeric modifications **X** and **Y**, with an additional hydroxymethyl group added to the bicyclic sugar unit of nucleoside **P**. We envisaged the use of the hydroxymethyl group as a major groove facing conjugation site for the attachment of different moieties, such as oligopeptides, oligonucleotides, pyrene units and alkylamines. Very few ONs carrying additional functionalities facing the major groove have been synthesized, but a pyrene conjugate of an *ara*-uridine monomer showed promising hybridization properties when targeting complementary DNA.**²⁹** However, the *ara*uridine monomer itself displayed destabilizing behaviour when

† Electronic supplementary information (ESI) available: copies of 13C NMR spectra of compounds **6–9** and copies of 31P NMR spectra of compounds **5** and **10**. See http://www.rsc.org/suppdata/ob/b4/b414454f/ ‡ A research center funded by the Danish National Research Foundation for studies on nucleic acid chemical biology.

 $R = CH₂OH$
 $R = CH₂OCH₃$ **Fig. 1**

incorporated into an ON and evaluated against complementary DNA and RNA.

Modifications **X** and **Y** showed a slight destabilizing effect when incorporated into a mixed 9-mer sequence and measured against a complementary RNA, with a profound destabilizing effect against complementary DNA.**²⁸** However, an almost fully modified 5 -**X**13T sequence displayed enhanced thermal stability towards complementary RNA as observed for the parent modification **P**. Surprisingly, thermal stability studies showed that modification **Y** induced a strong self-complexation when incorporated into an almost fully modified 5 -**Y**13T sequence (**ON3**, Table 1).**²⁸** We suggested that the presence of the 2 - *C*-hydroxymethyl group pointing towards the thymine moiety plays an important role in this observation. It is likely that the normal Watson–Crick base pairing is disrupted by hydrogen bonding between the hydroxyl group and the C2 carbonyl group. To study this hypothesis, and to evaluate the influence of the stereochemical configuration on the applicability as an attachment site, we decided to synthesize ONs containing the corresponding methylated monomer **Z** as a probe without the capability of forming a hydrogen bond with the C2 carbonyl group. In addition, the RNA binding observed for ONs containing **X** prompted us to investigate the applicability of the hydroxymethyl moiety of this monomer for functionalization towards the major groove of nucleic acid duplexes. This is an

Table 1 Thermal denaturation studies at 110 mM [Na+]/pH 7*^a*

		DNA target		RNA target	
Entry	ON sequence	$T_{\rm m}$	ΔT_m	$T_{\rm m}$	$\Delta T_{\rm m}$
Ref A ON1 ON ₂ ON3 ON4 ON ₅ ON ₆	$5'$ -T ₁₄ $5'$ -T ₇ $YT6$ $5'$ -T _s Y_4 T _s $5'$ - \mathbf{Y}_{13} T $5'$ -T ₇ ZT_6 $5'$ -T ₅ \mathbb{Z}_4 T ₅ $5'$ - \mathbb{Z}_1 ₃ T	31 27 10 60 27 10 n.d.	-4 -21 b -4 -21	29 25 25 61 24 25 38	b -5 -4 $+9$

 a Performed with 1.5 μ M of the two complementary strands in a medium salt buffer: 0.1 mM EDTA, 100 mM sodium chloride, 10 mM sodium phosphate, pH 7.0. The melting temperature T_m was determined as the maximum of the first derivative of the melting curve $(A_{260}$ vs. temperature). $\Delta T_{\text{m}} =$ difference in T_{m} obtained for the modified ON and for **Ref A**. n.d. = no transition detected above 10 \degree C. *b* A value of 61 *◦*C was obtained in an analogous thermal denaturation experiment without the addition of complementary strand.

extension of earlier work focused on utilizing modification **Y** as a branching point for triple helix forming ONs,**³⁰** elaborated upon herein by the introduction of the *N*-methylpiperazinomodified monomer **W**, a molecular design stimulated by the opportunity of exploratory *N*-derivatizations.**31,32** The basic *N*methylpiperazino moiety allows for studies relating duplex stability with changes in pH value or salt concentration, with the goal of advancing understanding regarding the relation between net charge and duplex stability.

Results and discussion

The phosphoramidite derivatives **5** and **10** were synthesized from the known bicylic nucleoside **1** (Scheme 1).**²⁸** Methylation at the 2 -*C*-hydroxymethyl position using conditions previously employed**26,33** to avoid methylation in the nucleobase moiety gave nucleoside **2** in 55% yield together with 26% recovered starting material. As expected, no N3-methylated product was observed.

Scheme 1 *Reagents and conditions*: i) CH₃I, NaH, anhydrous THF, 0 [°]C, 55% (+26% 1); ii) 20% Pd(OH)₂/C, H₂, abs. EtOH (for **3**) or acetone (for **7**), rt; iii) DMTCl, anhydrous pyridine, DMAP (synthesis of **9**), rt, **4**: 74% and **9**: 72% (two steps); iv) 2-cyanoethyl N , N -diisopropylphosphoramidochloridite, DIPEA, CH₂Cl₂, 5: 65% and **10**: 75%; v) TEMPO, BAIB, CH₂Cl₂, H₂O, 5 °C, 82%; vi) 1-methylpiperazine, CDI, anhydrous THF, rt, 85%; vii) DNA synthesizer. $\vec{T} = \hat{t}$ hymin-1-yl.

Oxidation of the 2 -*C*-hydroxymethyl position in nucleoside **1** by means of the free radical 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO) and iodobenzene diacetate (BAIB)**34,35** afforded the carboxylic acid **6** in a yield of 82%. The synthesis of amide **7** was initially attempted using either dicyclohexylcarbodiimide (DCC) or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) as coupling reagents, but formation of byproducts was observed in both cases. However, activation of the carboxylic acid by 1,1 -carbonyldiimidazole (CDI) in anhydrous THF, followed by addition of *N*-methylpiperazine smoothly converted nucleoside **6** into amide **7** in a satisfactory yield of 85%. The presence of an amine moiety in nucleoside **7** greatly enhanced the affinity for hydrophilic solvents and a strong basic aqueous solution had to be applied during workup in order to prevent the product entering the water phase. Hydrogenolysis of nucleosides 2 and 7, using H_2 and $Pd(OH)_2$ on carbon as a catalyst, afforded the debenzylated nucleosides **3** and **8**, respectively. The use of MeOH or EtOH as solvents only resulted in partial debenzylation of nucleoside **7**, whereas the use of acetone gave the fully debenzylated product. Selective protection of the primary hydroxyl group of crude derivatives **3** and **8** was accomplished using 4,4 -dimethoxytrityl chloride (DMTCl) in anhydrous pyridine, giving nucleosides **4** and **9** in overall yields of 74% and 72% from **2** and **7**, respectively. 4-(*N*,*N*-Dimethylamino)pyridine (DMAP) was added to the reaction mixture of nucleoside **8** in order to accelerate the reaction. Reacting nucleosides **4** and **9** with 2-cyanoethyl *N*,*N*diisopropylphosphoramidochloridite and DIPEA in anhydrous DCM afforded the phosphoramidites **5** and **10** in yields of 65% and 75%, respectively. **This is The Anti-Columbus and the 11 O-MV ([View Article Online](http://dx.doi.org/10.1039/b414454f) of the Results of the Results Chained on the Results Chain and the CHAIN CONTROLL INTERFERENCE CONTROLL INTERFERENCE CONTROLL INTERFERENCE CONTROLL INTERFERE**

Phosphoramidite **5** was used as a building block for the incorporation of monomer **Z** into modified 14-mer thymidylate sequences (**ON4–ON6**, Table 1; see Experimental section for details). As anticipated, and opposed to that observed for monomer **Y**²⁸, no self-complexation was observed for 5'-**Z**₁₃T (**ON6**). In fact, this modified ON displayed similar hybridization properties to 5'- $P_{13}T^{27}$ and 5'- $X_{13}T^{28}$ with an increased affinity towards complementary RNA (ΔT_{m} = +9 °C) and RNA selective hybridization. One or four consecutive modifications of **Z** induced a moderate decrease in the thermal stability toward RNA (**ON4** and **ON5**, Table 1), which is in agreement with results reported for ONs containing modification **Y** (**ON1** and **ON2**, Table 1)**²⁸** and also corresponds well with the behaviour of ONs modified with the parent compound **P**. **²⁷** The thermal stability studies of ONs modified with **Z** indicate that the RNA binding capability is preserved when the C2"-hydroxylmethyl moiety is chemically functionalized, which underlines the potential of this group as a conjugation site independent of stereochemical configurations at C2 .

The piperazino-functionalized monomer **W** was successfully incorporated into mixed 9-mer ONs but attempts to produce fully or partly substituted 14-mer oligothymidylates failed as the ONs obtained proved unstable under the conditions of deprotection and cleavage from the solid support (**ON7–ON9**, Table 2; see Experimental section for details). Thus, MALDI-MS and CE showed the removal of several piperazino moieties during the treatment with aqueous ammonia. The observed lack of stability was somewhat of a surprise to us since alkyl amide linkages are generally known to be compatible with the conditions of ON cleavage from solid supports,**36,37** and it is therefore likely that the observed amide hydrolysis occurs under the influence of the nearby thymine moiety. The thermal stability studies of the mixed 9-mers ONs were conducted in medium salt concentration (pH 5 and pH 7, Table 2) and in low salt concentration (pH 5 and pH 7, Table 3). For the reference ONs, **Ref B** and **Ref C** (Table 2 and 3), a destabilizing effect was observed when the salt concentration was reduced from 110 mM $[Na^+]$ to 40 mM $[Na^+]$, as expected owing to a less efficient shielding of the negatively charged backbones of the two hybridizing strands. Likewise, the reference ON was destabilized

Table 2 Thermal denaturation studies at 110 mM [Na+] *a*

	ON sequence	pH 7 ^b				pH 5 ^c			
		DNA target		RNA target		DNA target		RNA target	
Entry		$T_{\rm m}$	$\Delta T_{\rm m}$	$T_{\rm m}$	$\Delta T_{\rm m}$	$T_{\rm m}$	$\Delta T_{\rm m}$	$T_{\rm m}$	$\Delta T_{\rm m}$
Ref B	5'-d(GTG-ATA-TGC)	29		26		24		21	
ON7	5'-d(GTG-AWA-TGC)	27	-2	24	-2	24	θ	21	θ
ON ₈	5'-d(GWG-AWA-WGC)	19	-10	21	-5	20	-4	22	$+1$
Ref C	$5'$ -d(GT ^L G-ATA-T ^L GC)	36		41		32		38	
ON ₉	$5'$ -d(GT ^L G-AWA-T ^L GC)	34	-2	39	-2	32	θ	38	θ

^a See caption below Table 1.

^b 0.1 mM EDTA, 100 mM sodium chloride, 10 mM sodium phosphate, pH 7.0. *^c* 0.1 mM EDTA, 100 mM sodium chloride, 10 mM sodium acetate, pH 5.

Table 3 Thermal denaturation studies at 40 mM [Na+] *a*

^a See caption below Table 1. *^b* 0.1 mM EDTA, 30 mM sodium chloride, 10 mM sodium phosphate, pH 7.0. *^c* 0.1 mM EDTA, 30 mM sodium chloride, 10 mM sodium acetate, pH 5.

when the pH was lowered, which confirms that Watson–Crick base-pairing is disturbed at a low pH value,**38,39** and no thermal transition was observed for **Ref B** at a low salt concentration and pH 5. When a single **W** monomer was introduced in the mixed 9-mer (**ON7**, Table 2) we observed a slight decrease in T_m value when measuring against complementary DNA and RNA at pH 7. The effect was even more pronounced with three **W** monomers incorporated (**ON8**, Table 2). Lowering the pH appeared to change the situation as **ON7** no longer showed any destabilization compared to the reference, and **ON8** also showed a slight improvement ($\Delta T_m = +1 °C$) when measured against RNA at pH 5. This data suggests that the tertiary amine functionality of the piperazino group of monomer **W** experiences a higher degree of protonation at pH 5 than at pH 7.

The influence of the salt concentration was investigated by thermal stability studies as depicted in Table 3. Duplexes of **ON7** and **ON8** with complementary DNA and RNA targets were, relative to those involving **Ref B**, more stable at 40 mM [Na+]/pH 7 than at 110 mM [Na+]/pH 7 (see Table 2). In agreement, for **ON7** there is no decrease in T_m value towards complementary DNA and only a slight decrease ($\Delta T_m = -1 \,^{\circ}\mathrm{C}$) towards RNA. This observation suggests that the tertiary amine functionality of the piperazino group is at least partly protonated under the experimental conditions applied, and that this protonation plays a role in duplex stabilization. Clearly, the effect of lowering the pH value is even more pronounced at a low salt concentration than at a medium salt concentration. We established this by thermal denaturation studies at 40 mM [Na+]/pH 5 which showed no thermal transition for **Ref B** but a clear transition for **ON7** and **ON8**.

To study the compatibility of monomer **W** with LNA monomers**40,41** with the aim of enhancing the thermal stability of duplexes involving the modified 9-mer sequences, we incorporated two LNA-T monomers (Fig. 1) into **ON9**. As anticipated, the favorable hybridization properties of LNA significantly improved the thermal stability of duplexes formed with both DNA and RNA target strands (**Ref C**, Table 2 and Table 3). **ON9**, containing one **W** monomer and two LNA-T monomers, displayed the same tendency as **ON7** under both medium and low salt conditions (pH 7). However, at pH 5, only a negligible positive effect of the piperazino group was observed. These results indicate that under all of the conditions studied, the dominating affinity enhancing effect of the LNA monomers renders the effect of protonation of the basic piperazino group to be of less importance.

Conclusion

The applicability of a 2"-C-hydroxymethyl group of a 2',3'bicyclic nucleic acid monomer as a site for conjugation has been demonstrated by satisfactory RNA-binding of the corresponding O-methylated derivative **Z**. Attachment of a piperazino group to the 2 ,3 -bicyclic nucleic acid monomer *via* an amide bond influences the stability of a duplex formed between both complementary DNA and RNA. Especially at low salt concentrations, the pH value plays a significant role in determining the stability of duplexes involving the modified ONs, indicating that protonation of the tertiary amine plays a duplex-stabilizing role by partial charge reduction of the duplex. The binding affinity of an ON containing a single piperazino monomer could be further improved by incorporation of LNA-T monomers. These results demonstrate that functionalized 2 -*O*,3 -*C*-linked bicyclic nucleic acid monomers, *e.g.* **Y** (O-conjugation) and **W** (Nconjugation), are promising scaffolds for attachment of groups facing the major groove of nucleic acid duplexes for modulation of hybridization properties or for systematic mapping of the major groove.

Experimental

General

All reagents were obtained from commercial suppliers and used without further purification. THF was distilled from Na and benzophenone. Reactions were carried out under an atmosphere of nitrogen when anhydrous solvents were used. Column chromatography was performed using silica gel 60 (0.040–0.063 mm). Dichloromethane (DCM) used for column chromatography was distilled prior to use. NMR spectra were recorded on a Varian Gemini 200 NMR spectrometer or a Varian Unity 400 with chemical shift values relative to tetramethylsilane as an internal standard $(^1H$ and ^{13}C NMR) and relative to 85% H_3PO_4 as external reference (³¹P NMR). 2D NMR techniques were used to assign H and H ¹³C spectra. Coupling constants (*J* values) are given in Hz. Microanalyses were performed at the Microanalytical Laboratory, Department of Chemistry, University of Copenhagen. Matrix-assisted laserdesorption ionization-mass spectrometry (MALDI-MS) was performed on a 4.7 Tesla Ultima (IonSpec, Irvine, CA) Fourier transform ion cyclotron resonance (FTICR) mass spectrometer.

(1*S***,3***R***,5***R***,6***R***,8***R***)-5-Benzyloxy-6-benzyloxymethyl-3-methoxymethyl-8-(thymin-1-yl)-2,7-dioxabicyclo[3.3.0]octane (2).** Nucleoside **1²⁸** (810 mg, 1.64 mmol) was coevaporated with anhydrous acetonitrile $(3 \times 10 \text{ cm}^3)$ and redissolved in anhydrous THF (15 cm3). The solution was cooled to 0 *◦*C and NaH (197 mg of a 60% dispersion in oil, 4.91 mmol) was added. The mixture was stirred for 25 min followed by dropwise addition of $CH₃I$ (0.51 cm³, 8.18 mmol) over 30 min. After 3 h 50 min the reaction was quenched by the addition of ice cold water (8 cm^3) and the mixture was diluted with EtOAc (50 cm^3) . The mixture was washed with sat. aq. NaHCO₃ $(3 \times 30 \text{ cm}^3)$ and the separated organic phase was dried (Na_2SO_4) and evaporated to dryness under a reduced pressure. The residue was purified by silica gel column chromatography using EtOAc in petroleum ether $[30:70 \, (v/v)]$ as eluent to afford nucleoside **2** (454 mg, 55%) as a white solid material along with recovered starting material **1** (208 mg, 26%). δ_c (CDCl₃) 163.5, 150.0, 138.5, 137.2, 108.5, 93.9, 84.6, 82.5, 80.6, 79.2, 73.4, 72.2, 68.6, 67.1, 59.2, 33.6, 12.4. Calc. for $C_{28}H_{32}N_2O_7 \cdot 0.25H_2O$ requires C, 65.6; H, 6.4; N, 5.5; found C, 65.7; H, 6.5; N, 5.3%. FAB-MS m/z found 509.2 [M + H]⁺; requires 508.6.

(1*S***,3***R***,5***R***,6***R***,8***R***)-6-((4,4 -Dimethoxytrityl)oxymethyl)-5-hydroxy-3-methoxymethyl-8-(thymin-1-yl)-2,7-dioxabicyclo[3.3.0] octane (4).** Nucleoside **2** (488 mg, 0.96 mmol) was dissolved in abs. EtOH (10 cm³) and 20% Pd(OH)₂/C (110 mg) was added. The reaction mixture was flushed with hydrogen gas several times and was stirred vigorously under an atmosphere of hydrogen for 54 h. The catalyst was removed by filtration and the solvent was removed under a reduced pressure giving an intermediate product as a white solid material (302 mg; tentatively assigned as **3**). This solid material was coevaporated with anhydrous pyridine $(3 \times 5 \text{ cm}^3)$ and redissolved in anhydrous pyridine (4 cm³). DMTCl (399 mg, 1.18 mmol) was added and the mixture was stirred at rt for 24 h whereupon additional DMTCl (200 mg, 0.59 mmol) was added. After 120 h the reaction mixture was poured into a mixture of petroleum ether-DCM-H₂O [20 cm³, 1 : 1 : 1, $v/v/v$]. The organic phase was separated, washed with sat aq. $NaHCO₃$ $(3 \times 5 \text{ cm}^3)$, dried (Na₂SO₄), and evaporated to dryness under a reduced pressure. The residue was purified by silica gel column chromatography using MeOH and pyridine [0–1.5% MeOH, 0.5% pyridine $(v/v/v)$] in DCM as eluent affording nucleoside **4** (450 mg, 74%) as a white solid material. δ_c (CDCl₃) 163.4, 158.4, 150.5, 149.5, 144.4, 138.4, 135.9, 135.7, 135.3, 129.9, 129.8, 127.9, 127.8, 126.8, 123.7, 113.1, 109.1, 88.5, 87.4, 86.7, 82.2, 80.5, 80.0, 72.6, 62.3, 59.2, 55.1, 37.1, 12.3. Calc. for $C_{35}H_{38}N_2O_9.0.33H_2O.0.33pyridine requires C, 66.4; H, 6.1; N,$ 4.9; found C, 66.0; H, 6.1; N, 4.9%. FAB-MS *m*/*z* found 631.4 $[M + H]^{+}$; requires 630.7.

(1*S***,3***R***,5***R***,6***R***,8***R***)-5-(2-Cyanoethoxy(diisopropylamino)phosphinoxy)-6-((4,4 -dimethoxytrityl)oxymethyl)-3-methoxymethyl-8-(thymin-1-yl)-2,7-dioxabicyclo[3.3.0]octane (5).** Nucleoside **4** (240 mg, 0.38 mmol) was coevaporated with anhydrous acetonitrile $(3 \times 1 \text{ cm}^3)$ and redissolved in anhydrous DCM

(2.5 cm3) under stirring. The solution was cooled to 0 *◦*C and *N*,*N*-diisopropylethylamine (0.20 cm³, 1.15 mmol) was added followed by dropwise addition of 2-cyanoethyl *N*,*N*diisopropylphosphoramidochloridite (0.13 cm³, 0.58 mmol) over 10 min. The mixture was stirred for 1 h at rt. Additional N , N -diisopropylethylamine $(0.20 \text{ cm}^3, 1.15 \text{ mmol})$ and 2-cyanoethyl *N*,*N*-diisopropylphosphoramidochloridite (0.13 cm3 , 0.58 mmol) was added at 0 *◦*C and the mixture was stirred for 2 h at room temperature. The reaction was quenched by the addition of anhydrous MeOH (0.05 cm^3) and the mixture diluted with DCM (30 cm^3) . The resulting mixture was washed successively with sat. aq. NaHCO₃ (3 \times 15 cm³), dried (Na_2SO_4), and evaporated to dryness under a reduced pressure. The residue was purified by silica gel column chromatography using EtOAc, *n*-heptane and triethylamine [45 : 45 : 10 (v/v/v)] as eluent to give amidite **5** (204 mg, 65%) as a white solid material. δ_P (DMSO- d_6) 142.8, 142.7.

(1*S***,3***R***,5***R***,6***R***,8***R***)-5-Benzyloxy-6-benzyloxymethyl-3-carboxy-8-(thymin-1-yl)-2,7-dioxabicyclo[3.3.0]octane (6).** Nucleoside **1²⁸** (2.70 g, 5.47 mmol) was dissolved in a mixture of DCM (5 cm^3) and H₂O (5 cm³) followed by addition of BAIB (3.80 g, 11.80 mmol) and the free radical TEMPO (100 mg, 0.64 mmol). The heterogeneous reaction mixture was stirred for 48 h at 5 °C followed by addition of sat. aq. Na₂S₂O₃ (5 cm³). The resulting mixture was extracted with EtOAc $(4 \times 30 \text{ cm}^3)$ and the combined organic phase was washed with H_2O (10 cm³), dried (Na₂SO₄), and evaporated to dryness under a reduced pressure. The residue was washed with $Et_2O(20 \text{ cm}^3)$, dissolved in a mixture of MeOH and DCM $[5:95 (v/v)]$, and purified by filtering through a short silica gel pad using a mixture of MeOH and DCM as eluent [5 : 95 (v/v)] to give nucleoside **6** as a white solid material (2.30 g, 82%). $\delta_{\rm H}$ (DMSO-*d*6) 11.33 (1H, s, NH), 7.71 (1H, s, 6-H), 7.31–7.21 (10H, m, Ar), 6.00 (1H, d, *J* 4.4, $1'$ -H), 4.63–4.43 (6H, m, 2"-H and 2'-H and CH₂Ph), 4.17 (1H, t, *J* 5.9, 4 -H), 3.74 (2H, d, *J* 5.8, 5 -H2), 2.48 (1H, dd, *J* 5.7 and 13.8, 1["]-H_a), 2.17 (1H, dd, *J* 11.0 and 13.1, 1"-H_b), 1.72 $(3H, s, CH₃)$. δ_C (DMSO-*d*6) 172.0 (COOH), 163.7 (C-4), 150.3 (C-2), 139.3 (C-6), 138.1, 138.0, 128.2, 127.6 and 127.4 (Ar), 107.5 (C-5), 93.3 (C-3'), 84.4 (C-2'), 81.5 (C-1'), 79.5 (C-2"), 78.2 $(C-4')$, 72.3 (CH_2Ph) , 68.5 $(C-5')$, 66.5 (CH_2Ph) , 36.0 $(C-1'')$, 12.0 (CH₃). MALDI-MS m/z 531 [M + Na]⁺. HRMS requires *m*/*z* 531.1738; found 531.1720. View Most Control on 18 November 2011 and the college of 2011 and 2013. The main of the control of 2013. The main of 2013. The main

> **(1***S***,3***R***,5***R***,6***R***,8***R***)-5-Benzyloxy-6-benzyloxymethyl-3-((***N***-methylpiperazino)carbonyl)-8-(thymin-1-yl)-2,7-dioxabicyclo[3.3.0] octane (7).** CDI (512 mg, 3.16 mmol) was added to a solution of nucleoside **6** (978 mg, 1.93 mmol) in anhydrous THF (10 cm3) and the solution was stirred for 1 h at rt. *N*-Methylpiperazine ($652 \mu l$, $5.86 \mu mol$) was added dropwise and the reaction mixture was stirred for additional 2 h followed by evaporation to dryness under a reduced pressure. The residue was dissolved in EtOAc (50 cm^3) and the organic phase was washed with 10% aq. NaOH (2×10 cm³), dried (Na₂SO₄), and evaporated to dryness under a reduced pressure. The residue was purified by column chromatography using MeOH and MeOH saturated with NH₃ [0–3% MeOH, 1% NH₃–MeOH (v/v/v)] in DCM as eluent to give nucleoside 7 as a white foam (967 mg, 85%). $\delta_{\rm H}$ (CDCl3) 9.58 (1H, s, NH), 7.38–7.26 (11H, m, 6-H and Ar), 6.04 (1H, d, *J* 4.4, 1'-H), 4.81 (1H, dd, *J* 5.9 and 10.9, 2"-H), 4.74 (1H, d, *J* 4.9, 2 -H), 4.64–4.52 (4H, m, CH2Ph), 4.25 (1H, t, *J* 5.6, 4'-H), 3.92–3.85 (1H, m, NCH₂), 3.85 (2H, d, J 5.6, 5'-H₂), 3.66–3.62 (1H, m, NCH₂), 3.40–3.28 (2H, m, NCH₂), 2.70 (1H, dd, *J* 10.4 and 14.3, 1"-H_a), 2.56–2.46 (2H, m, NCH₂), 2.29 $(1H, dd, J 12.0 \text{ and } 14.2, 1 - H_b)$, 2.24 (3H, s, NCH₃), 2.14–2.01 (2H, m, NCH₂), 1.89 (3H, s, CH₃). δ_c (CDCl₃) 166.0 (CO), 163.9 (C-4), 150.4 (C-2), 138.1 (C-6), 137.5, 137.4, 128.7, 128.6, 128.1, 128.0, 127.9 and 127.3 (Ar), 109.2 (C-5), 93.4 (C-3), 85.8 (C-2'), 82.9 (C-1'), 79.3 (C-4'), 78.8 (C-2"), 73.7 (CH₂Ph), 68.8 $(C-5')$, 67.6 (CH_2Ph) , 55.4 and 54.5 (NCH₂), 45.9 (NCH₃), 45.4

and 42.1 (NCH₂), 34.6 (C-1"), 12.4 (CH₃). MALDI-MS m/z 613 [M + Na]+. HRMS requires *m*/*z* 613.2633; found 613.2614.

(1*S***,3***R***,5***R***,6***R***,8***R***)-5-Hydroxy-6-hydroxymethyl-3-((***N***-methylpiperazino)carbonyl)-8-(thymin-1-yl)-2,7-dioxabicyclo[3.3.0]octane (8).** 20% $Pd(OH)₂/C$ (200 mg) was added to a solution of nucleoside 7 (900 mg, 1.52 mmol) in acetone (15 cm^3) and the reaction mixture was flushed with hydrogen gas and stirred under an atmosphere of hydrogen for 24 h at rt. The reaction mixture was filtered and the filtrate was evaporated to dryness affording nucleoside **8** as white foam (563 mg, 90%). $\delta_{\rm H}$ (DMSO- d_6) 11.41 (1H, s, NH), 7.46 (1H, s, 6-H), 6.05 (1H, s, OH), 5.86 (1H, d, *J* 5.0, 1 -H), 4.98 (1H, dd, *J* 5.1 and 10.7, 2-H), 4.97 (1H, s, OH), 4.33 (1H, d, *J* 4.6, 2 -H), 3.76–3.58 (7H, m, 4 -H, 5 -H2 and NCH2), 3.19–3.12 (2H, m, NCH2), 2.74–2.58 (2H, m NCH₂), 2.63 (3H, s, NCH₃), 2.27 (1H, dd, *J* 11.4 and 13.5, $1^{\prime\prime}$ -H_a), 2.01 (1H, dd, *J* 5.2 and 13.3, $1^{\prime\prime}$ -H_b), 1.73 (CH₃). δ_c (DMSO- d_6) 167.2 (CO), 163.8 (C-4), 150.2 (C-2), 138.5 (C-6), 107.5 (C-5), 88.2 (C-2), 86.8 (C-3), 82.5 (C-4), 81.8 (C-1), 77.8 $(C-2)$, 59.5 $(C-5)$, 52.9 and 52.3 (NCH₂), 42.5 (NCH₃), 42.2 and 38.9 (NCH₂), 37.4 (C-1"), 12.1 (CH₃). MALDI-MS m/z 433 $[M + Na]^{+}$. Published on 18 November 2004. Downloaded on 08/05/2016 20:30:32. [View Article Online](http://dx.doi.org/10.1039/b414454f)

(1*S***,3***R***,5***R***,6***R***,8***R***)-6-((4,4 -Dimethoxytrityl)oxymethyl)-5-hydroxy-3-((***N***-methylpiperazino)carbonyl)-8-(thymin-1-yl)-2,7-dioxabicyclo[3.3.0]octane (9).** DMTCl (495 mg, 1.46 mmol) and DMAP (30 mg, 0.25 mmol) were added to a solution of nucleoside **8** (501 mg, 1.22 mmol) in anhydrous pyridine (10 cm3). The reaction mixture was stirred for 18 h at rt and evaporated to dryness under a reduced pressure. The residue was dissolved in EtOAc (20 cm³) and washed successively with sat. aq. NaHCO₃ $(3 \times 5 \text{ cm}^3)$ and H₂O (5 cm^3) , dried $(Na₂SO₄)$, and evaporated to dryness under a reduced pressure. The residue was purified by column chromatography using MeOH and MeOH saturated with NH₃ [0–3% MeOH, 1% NH3–MeOH (v/v/v)] in DCM as eluent to give nucleoside **9** as a white solid material (698 mg, 80%). δ_H (DMSO- d_6) 11.41 (1H, s, NH), 7.45–7.23 (10H, m, Ar and 6-H), 6.89 (4H, d, *J* 8.0), 5.97 (1H, d, *J* 5.0, 1 -H), 5.85 (1H, s, 3 -OH), 4.83 (1H, dd, *J* 5.2 and 10.8, 2"-H), 4.31 (1H, d, *J* 5.0, 2'-H), 4.01 (1H, dd, *J* 2.2 and 7.4, 4'-H), 3.74 (6H, s, OCH₃), 3.74–3.53 (2H, m, NCH₂), 3.36–3.06 (4H, m, 5'-H₂ and NCH₂), 2.47 (2H, m, NCH₂), 2.16 (1H, dd, *J* 10.9 and 13.3, 1"-H_a), 2.09 (NCH₃), 1.86 (2H, m, NCH₂), 1.75 (1H, m, 1"-H_b), 1.73 (3H, s, CH₃). δ_c (DMSO- d_6) 166.1 (CO), 163.6 (C-4), 158.1 (Ar), 150.0 (C-2), 144.7 and 137.4 (C-6), 135.4, 135.2, 129.7, 127.8, 127.7, 126.7 and 113.2 (Ar), 107.5 (C-5), 87.9 (C-2), 86.6 and 85.7 (C-3 and Ar₃C), 82.1 (C-1'), 80.2 (C-4'), 77.9 (C-2"), 62.0 (C-5'), 55.0 $(OCH₃)$, 54.9, 54.0 (NCH₂), 45.4 (NCH₃), 44.8 (NCH₂), 41.4 (NCH₂), 37.3 (C-1"), 12.1 (CH₃). MALDI-MS m/z 735 [M + Na]+. HRMS *m*/*z* requires 735.3001; found 735.3016.

(1*S***,3***R***,5***R***,6***R***,8***R***)-5-(2-Cyanoethoxy(diisopropylamino)phosphinoxy)-6-((4,4 -dimethoxytrityl)oxymethyl)-3-((***N***-methylpiperazino)carbonyl)-8-(thymin-1-yl)-2,7-dioxabicyclo[3.3.0]octane (10).** 2-Cyanoethyl*N*,*N*-diisopropylphosphoramidochloridite (0.26 cm3 , 1.16 mmol) was added dropwise to a stirred solution of nucleoside **9** (410 mg, 0.576 mmol) in a mixture of anhydrous DCM (2.5 cm^3) and *N*,*N*-diisopropylethylamine (0.5 cm^3) . The reaction mixture was stirred for 12 h at rt and subsequently evaporated to dryness under a reduced pressure. The residue was purified by silica gel column chromatography using triethylamine and acetone [2 : 98 (v/v)] as eluent to give amidite **10** (395 mg, 75%) as a white solid material. δ_P (DMSO- d_6) 142.9, 142.6.

Oligonucleotide synthesis

All ONs were prepared on a Biosearch 8700 synthesizer using the phosphoramidite approach. Amidite **5** or **10** were used as building blocks for incorporation of monomers **Z** and **W** into ONs using a 10 min coupling time with pyridinium hydrochloride as an activator and *tert*-butyl hydroperoxide as an oxidant in step-wise coupling yields of 98%. The DNA and LNA-T nucleotides were incorporated in step-wise coupling yields of >99% (2 min and 6 min coupling times, respectively.) The 5 -*O*-DMT-OFF ONs were deprotected using concentrated NH3 in MeOH for 12 h at 55 *◦*C. Precipitation from EtOH afforded ONs of >80% purity as evaluated by gel capillary electrophoresis. The composition of the ON's was verified by MALDI-MS [M − H] analysis: **ON4** calc. 4282; found 4276: **ON5** calc. 4539; found 4539: **ON6** calc. 5312; found 5313: **ON7** calc. 2922; found 2921: **ON8** calc. 3258; found 3256: **ON9** calc. 2976; found 2978.

Acknowledgements

The Danish Research Agency and the Danish National Research Foundation are thanked for financial support. Ms Britta M. Dahl, Department of Chemistry, University of Copenhagen, is thanked for oligonucleotide synthesis and Dr Michael Meldgaard, Exiqon A/S, for MALDI-MS analysis.

References

- 1 J. Wengel, *Org. Biomol. Chem.*, 2004, **2**, 277.
- 2 K. F. Pirollo, A. Rait, L. S. Sleer and E. H. Chang, *Pharmacol. Ther.*, 2003, **99**, 55.
- 3 L. E. Heystek, H. Zhou, P. Dande and B. Gold, *J. Am. Chem. Soc.*, 1998, **120**, 12165.
- 4 A. M. Soto, B. I. Kankia, P. Dande, B. Gold and L. A. Marky, *Nucleic Acids Res.*, 2002, **30**, 3171.
- 5 T. P. Prakash, D. A. Barawkar, V. Kumar and K. N. Ganesh, *Bioorg. Med. Chem. Lett.*, 1994, **4**, 1733.
- 6 K. S. Ramasamy, M. Zounes, C. Gonzales, S. M. Freier, E. A. Lesnik, L. L. Cummins, R. H. Griffey, B. P. Monia and P. D. Cook, *Tetrahedron Lett.*, 1994, **35**, 215.
- 7 M. Manoharan, K. S. Ramasamy, V. Mohan and D. P. Cook, *Tetrahedron Lett.*, 1996, **37**, 7675.
- 8 M. A. Maier, I. Barber-Peoc'h and M. Manoharan, *Tetrahedron Lett.*, 2002, **43**, 7613.
- 9 H. Hashimoto, M. G. Nelson and C. Switser, *J. Am. Chem. Soc.*, 1993, **115**, 7128.
- 10 F. Seela and M. Zulauf, *Helv. Chim. Acta*, 1999, **82**, 1878.
- 11 K.-Y. Lin and M. D. Matteucci, *J. Am. Chem. Soc.*, 1998, **120**, 8531. 12 R. L. Letsinger, C. N. Singman, G. Histand and M. Salunkhe, *J. Am. Chem. Soc.*, 1988, **110**, 4470.
- 13 P. M. Jung, G. Histand and R. L. Letsinger, *Nucleosides Nucleotides*, 1994, **13**, 1597.
- 14 T. Horn, S. Chaturvedi, T. N. Balasubramaniam and R. L. Letsinger, *Tetrahedron Lett.*, 1996, **37**, 743.
- 15 R. Fathi, Q. Huang, G. Coppola, W. Delaney, R. Teasdale, A. M. Krieg and A. F. Cook, *Nucleic Acids Res.*, 1994, **22**, 5416.
- 16 A. F. Cook, R. Fathi, Q. Huang, G. Coppola, W. Delaney and J.-L. Syi, *Nucleosides Nucleotides*, 1995, **14**, 1005.
- 17 T. Michel, F. Debart and J.-J. Vasseur, *Tetrahedron Lett.*, 2003, **44**, 6579.
- 18 D. T. Hickman, T. H. S. Tan, J. Morral, P. M. King, M. A. Cooper and J. Micklefield, *Org. Biomol. Chem.*, 2003, **1**, 3277.
- 19 R. Meier, S. Grüschow and C. Leumann, *Helv. Chim. Acta*, 1999, 82, 1813.
- 20 H. M. Pfundheller, T. Bryld, C. E. Olsen and J. Wengel, *Helv. Chim. Acta*, 2000, **83**, 128.
- 21 H. Aurup, T. Tuschl, F. Benseler, J. Ludwig and F. Eckstein, *Nucleic Acids Res.*, 1994, **22**, 20.
- 22 M. Kanazaki, Y. Ueno, S. Shuto and A. Matsuda, *J. Am. Chem. Soc.*, 2000, **122**, 2422.
- 23 R. H. Griffey, B. P. Monia, L. L. Cummins, S. Freier, M. J. Greig, C. J. Guinosso, E. Lesnik, S. M. Manalili, V. Mohan, S. Owens, B. R. Ross, H. Sasmor, E. Wancewicz, K. Weiler, P. D. Wheeler and P. D. Cook, *J. Med. Chem.*, 1996, **39**, 5100.
- 24 T. P. Prakash, M. Manoharan, A. S. Fraser, A. M. Kawasaki, E. L. Lesnik and S. R. Owens, *Tetrahedron Lett.*, 2000, **41**, 4855.
- 25 M. Prhavc, T. P. Prakash, G. Minasov, P. D. Cook, M. Egli and M. Manoharan, *Org. Lett.*, 2003, **5**, 2017.
- 26 G. Wang and W. E. Seifert, *Tetrahedron Lett.*, 1996, **37**, 6515.
- 27 P. Nielsen, H. M. Pfundheller, C. E. Olsen and J. Wengel, *J. Chem. Soc., Perkin Trans. 1*, 1997, 3423.
- 28 M. Raunkjær, C. E. Olsen and J. Wengel, *J. Chem. Soc., Perkin Trans. 1*, 1999, 2543.
- 29 N. N. Dioubankova, A. D. Malakhov, D. A. Stetsenko, M. J. Gait, P. E. Volynsky, R. G. Efremov and V. A. Korshun, *ChemBioChem*, 2003, **4**, 841.
- 30 M. D. Sørensen, M. Meldgaard, V. K. Rajwanshi and J. Wengel, *Bioorg. Med. Chem. Lett.*, 2000, **10**, 1853;; M. Meldgaard, M. Raunkjær, V. K. Rajwanshi, J. Wengel and M. D. Sørensen, *Bioorg. Med. Chem. Lett.*, 2001, **11**, 751. View Antibox (E. Oliver and J. West, Z. P. (2004. D. A. P. A. P.
	- 31 A preliminary report has been published: M. Raunkjær, T. Bryld and J. Wengel, *Chem. Commun.*, 2003, 1604.
	- 32 T. Bryld, T. Højland and J. Wengel, *Chem. Commun.*, 2004, 1064.
	- 33 H. M. Pfundheller, A. A. Koshkin, C. E. Olsen and J. Wengel, *Nucleosides Nucleotides*, 1999, **18**, 2017.
- 34 A. D. Mico, R. Margarita, L. Parlanti, A. Vescovi and G. Piancatelli, *J. Org. Chem*, 1997, **62**, 6974.
- 35 J. B. Epp and T. S. Widlanski, *J. Org. Chem.*, 1999, **64**, 293.
- 36 G. V. Petersen and J. Wengel, *Tetrahedron*, 1995, **51**, 2145.
- 37 J. Lebreton, A. D. Mesmaeker, A. Waldner, V. Fritsch, R. M. Wolf and S. M. Freier, *Tetrahedron Lett.*, 1993, **34**, 6383.
- 38 N. Sugimoto, P. Wu, H. Hara and Y. Kawamoto, *Biochemistry*, 2001, **40**, 9396.
- 39 I. Rouzina and V. A. Bloomfield, *Biophys. J.*, 2001, **80**, 894.
- 40 A. A. Koshkin, S. K. Singh, P. Nielsen, V. K. Rajwanshi, R. Kumar, M. Meldgaard, C. E. Olsen and J. Wengel, *Tetrahedron*, 1998, **54**, 3607.
- 41 S. Obika, D. Nanbu, Y. Hari, J.-I. Andoh, K.-I. Morio, T. Doi and T. Imanishi, *Tetrahedron Lett.*, 1998, **39**, 5401.